| Basics |
Denali Therapeutics Inc.
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
|
| IPO Date: |
December 8, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.06B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.80 | 2.76%
|
| Avg Daily Range (30 D): |
$0.33 | 2.27%
|
| Avg Daily Range (90 D): |
$0.41 | 2.93%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.55M |
| Avg Daily Volume (30 D): |
1.2M |
| Avg Daily Volume (90 D): |
1.2M |
| Trade Size |
| Avg Trade Size (Sh.): |
68 |
| Avg Trade Size (Sh.) (30 D): |
75 |
| Avg Trade Size (Sh.) (90 D): |
74 |
| Institutional Trades |
| Total Inst.Trades: |
3,136 |
| Avg Inst. Trade: |
$2.76M |
| Avg Inst. Trade (30 D): |
$2.45M |
| Avg Inst. Trade (90 D): |
$2.23M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.78M |
| Avg Closing Trade (30 D): |
$3.2M |
| Avg Closing Trade (90 D): |
$3.01M |
| Avg Closing Volume: |
134.24K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.78
|
$-.63
|
|
Diluted EPS
|
|
$-.78
|
$-.63
|
|
Revenue
|
$
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -132.97M
|
$ -107.19M
|
|
Operating Income / Loss
|
$
|
$ -145.58M
|
$ -123.19M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -116.48M
|
$ 15.96M
|
|
PE Ratio
|
|
|
|
|
|
|
